Viridian Therapeutics Beheer

Beheer criteriumcontroles 1/4

De CEO Viridian Therapeutics is Steve Mahoney, benoemd in Oct2023, heeft een ambtstermijn van 1.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 13.02M, bestaande uit 0.9% salaris en 99.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.028% van de aandelen van het bedrijf, ter waarde $ 519.37K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.1 jaar en 4.1 jaar.

Belangrijke informatie

Steve Mahoney

Algemeen directeur

US$13.0m

Totale compensatie

Percentage CEO-salaris	0.9%
Dienstverband CEO	1.1yrs
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	1.1yrs
Gemiddelde ambtstermijn bestuur	4.1yrs

Recente managementupdates

Recent updates

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Sep 12

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

May 15

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Apr 18

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Jan 08

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Sep 09

Viridian Therapeutics board compensation committee approves inducement grants

Sep 02

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Aug 22

Viridian Therapeutics Q2 2022 Earnings Preview

Aug 12

Analyse CEO-vergoeding

Hoe is Steve Mahoney's beloning veranderd ten opzichte van Viridian Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$228m
Mar 31 2024	n/a	n/a	-US$218m
Dec 31 2023	US$13m	US$113k	-US$238m

Compensatie versus markt: De totale vergoeding ($USD 13.02M ) Steve } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.36M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Steve te vergelijken met de prestaties van het bedrijf.

CEO

Steve Mahoney (53 yo)

1.1yrs

Tenure

US$13,022,654

Compensatie

Mr. Stephen F. Mahoney, also known as Steve, J. D. serves as President, CEO & Director at Viridian Therapeutics, Inc. since October 30, 2023. He served as President, Chief Financial and Operating Officer a...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Stephen Mahoney	CEO, President & Director	1.1yrs	US$13.02m	0.028% $ 519.4k
Seth Harmon	Senior VP of Finance and Accounting	1.2yrs	US$6.67m	0.0013% $ 24.3k
Thomas Beetham	Chief Operating Officer	1.1yrs	US$5.17m	0.0079% $ 145.6k
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Vahe Bedian	Co-Founder & Scientific Advisor	no data	geen gegevens	geen gegevens
Jennifer Tousignant	Chief Legal Officer	less than a year	geen gegevens	geen gegevens
John Jordan	Vice President of Investor Relations & Corporate Communications	no data	geen gegevens	geen gegevens
Melissa Manno	Chief Human Resources Officer	less than a year	geen gegevens	geen gegevens
Anthony Casciano	Chief Commercial Officer	1.6yrs	geen gegevens	geen gegevens
Thomas Ciulla	Chief Medical Officer	1.8yrs	geen gegevens	0.0010% $ 18.5k

1.1yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VRDN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.1 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Stephen Mahoney	CEO, President & Director	1.1yrs	US$13.02m	0.028% $ 519.4k
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Arlene Morris	Independent Director	6.8yrs	US$477.83k	0% $ 0
Victor Ambros	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Stefanie Dimmeler	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Jeffery Molkentin	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Eva van Rooij	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Tomas Kiselak	Independent Chairperson of Board	4.1yrs	US$503.83k	0% $ 0
Jennifer Moses	Independent Director	3.3yrs	US$467.83k	0% $ 0
Peter Harwin	Independent Director	4.1yrs	US$471.83k	0% $ 0

4.1yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VRDN wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).

Viridian Therapeutics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

CEO, President & Director recently bought US$499k worth of stock

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. Announces Executive Changes

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Recent updates

CEO, President & Director recently bought US$499k worth of stock

New major risk - Shareholder dilution

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Price target increased by 7.5% to US$37.81

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

New minor risk - Share price stability

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

Viridian Therapeutics, Inc. Announces Positive Clinical Activity Data for VRDN-001

Consensus revenue estimates fall by 19%

First half 2024 earnings: EPS and revenues miss analyst expectations

Viridian Therapeutics, Inc. Announces Completion of Thrive-2 Enrollment for Vrdn-001 in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?

Consensus revenue estimates increase by 21%

Price target decreased by 7.3% to US$36.50

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

New minor risk - Share price stability

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 15%, EPS upgraded

Price target decreased by 8.0% to US$40.07

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc. announced that it has received $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Price target decreased by 10% to US$41.36

Viridian Therapeutics, Inc. announced that it expects to receive $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Executive Changes

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates increase by 18%

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

President recently bought US$101k worth of stock

Consensus revenue estimates fall by 35%

President recently bought US$160k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Viridian Therapeutics, Inc. Appoints Scott Myers as Chief Executive Officer

Price target increased by 9.1% to US$47.08

Chief Medical Officer exercised options and sold US$708k worth of stock

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (Ted)

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Viridian Therapeutics Announces First Patient Enrolled in the ‘Thrive’ Phase 3 Trial in Patients with Thyroid Eye Disease

Consensus revenue estimates increase by 162%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new and inexperienced directors

Viridian Therapeutics, Inc Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Viridian Therapeutics, Inc. Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Viridian Therapeutics board compensation committee approves inducement grants

Consensus forecasts updated

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viridian Therapeutics, Inc. Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Price target increased to US$39.22

Viridian Therapeutics Q2 2022 Earnings Preview

Viridian Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer